Smith+Nephew account plan
medical devices for mobility
At a glance
Smith+Nephew is a medical technology group in orthopaedics, sports medicine and wound care: $6,164m revenue in 2025 and 16,988 employees.
Smith+Nephew is a portfolio medical technology company focused on the repair, regeneration and replacement of soft and hard tissue, selling hip and knee implants, the CORI surgical robot, arthroscopic and ENT devices, and advanced wound care products to surgeons, hospitals and ambulatory surgery centers in around 100 countries. About 50% of revenue comes from the US and 20% from Europe, through a specialist sales force of 3,850+. In 2025 revenue was $6,164m (+5.3% underlying), trading profit $1,211m (19.7% margin) and free cash flow $840m; the group had 16,988 employees. Its CEO is Deepak Nath, its CFO John Rogers and its Chair Rupert Soames.
Business units
Orthopaedics
40% of 2025 Group revenue ($2,437m)Hip, knee and shoulder implants, CORI handheld robotics and Trauma & Extremities, led by Craig Gaffin. 2025 revenue grew 5.1% underlying and the trading margin rose 340bps to 14.9%, but US Knee Implants lag for lack of a cementless knee; the cementless LANDMARK knee received FDA 510(k) clearance in September 2026. In Q3 2026 the unit returned to growth (+2.5%), and the Board is exploring strategic options for it.
Sports Medicine & ENT
31% of 2025 Group revenue ($1,934m)Arthroscopic implants, instruments and enabling technologies for joint repair, plus ENT devices, led by Scott Schaffner; 25% share of a $7.0bn sports medicine market. Revenue grew 5.2% underlying in 2025 and 7.9% in Q3 2026, led by REGENETEN, CARTIHEAL and TENDON SEAM, while ENT is held back by China channel inventory ahead of VBP.
Advanced Wound Management
29% of 2025 Group revenue ($1,793m)Dressings such as ALLEVYN, biologics and skin substitutes, SANTYL, and PICO and RENASYS negative pressure devices, led by Rohit Kashyap; 14% share of a $13.1bn wound market. 2025 trading profit rose 12.0% to $447m, but Bioactives fell 8.8% in Q3 2026 after the US skin-substitute reimbursement reset.
Strategic priorities
- RISE strategy
- Reach more patients (from more than 15 million to around 20 million in 2028), Innovate (more than 75 launches in five years), Scale through investment in Sports Medicine and Wound, and Execute efficiently.
- 2028 financial targets
- 6-7% organic revenue CAGR, 9-10% trading profit CAGR, free cash flow over $1 billion and 12-13% adjusted ROIC in 2028.
- Fixing US knees and Orthopaedics margin
- Fill the cementless gap with LANDMARK, expand CORI to hips (CORI Hip in Q1 2027), and lift the Orthopaedics trading margin by 300-400bps by 2028 and above 20% by 2030.
- Market leadership in Sports Medicine and Wound
- Prioritise investment in the higher growth and margin units, with the ambition to be "the number one Sports Medicine company in the world".
- Cost efficiency and automation
- Cumulative 12-Point Plan and zero-based budgeting savings reached $330m; 2026 savings are expected at around $200m, and a third wave aims to simplify and automate processes with new systems and AI, including a single global ERP.
Latest results
In Q3 2026 revenue was $1,551m, up 3.4% underlying, with Sports Medicine & ENT up 7.9%, Orthopaedics back to growth at 2.5% and Advanced Wound Management at -0.2%. Over nine months revenue was $4,648m (+2.7% underlying). H1 2026 trading profit was $566m (+8.1%), an 18.3% margin, and net debt $3,019m. On 4 November 2026 guidance was cut to around 3% underlying revenue growth, around 4% trading profit growth (around $1.25 billion), around $750m free cash flow and adjusted ROIC of around 9%, reflecting slower growth in US Orthopaedics.
Investments and deals
- Integrity Orthopaedics acquisition
- Acquired in January 2026 for $225m upfront plus up to $225m of performance payments over five years, adding TENDON SEAM rotator cuff repair.
- Melton wound manufacturing site
- A new wound plant at Melton near Hull, UK, due to start operations in 2027; capex rose $51m in H1 2026 for it and IT upgrades.
- R&D and robotics
- R&D of $296m in 2025, rising in 2026 to average over 5% of revenue; a five-year surgical robotics partnership with Imperial College London.
- Inventory portfolio rationalisation
- Phasing out 50 more product families, leaving 59 from 128, with an expected $500m reduction in capital employed; Orthopaedics manufacturing consolidated from eight core sites to three.
- Share buyback
- A $500m buyback announced on 6 May 2026, with $250m completed by the end of Q3.
Challenges and risks
- US Orthopaedics weakness
- US Knees fell 7.3% in Q3 2026, reflecting business lost in previous periods and the lack of a cementless offer across the installed base.
- US skin-substitute reimbursement reset
- Advanced Wound Bioactives declined as the market adapts more slowly than anticipated; the headwind is expected towards the upper end of the $20-40m range in 2026.
- China Volume Based Procurement
- China fell from about 7% of the business to around 2% by the end of 2025, and VBP is still expected in Arthroscopic Enabling Technologies and ENT.
- Tariffs and pricing pressure
- Tariffs, buying-group consolidation and commoditisation are named risks; the 2026 tariff impact of $60m is mostly offset by refunds.
- Portfolio pressure
- The Board approached Johnson & Johnson about a combination of Orthopaedics with DePuy Synthes; those talks ended and other strategic options are being explored.
What leadership says
“Orthopaedics is not where we want it to be, but we expect growth to accelerate as we fill portfolio gaps, starting later this year and continuing into 2027.”
“Targets matter, targets are sacrosanct, and we're going to do everything in our power to meet the targets that our investors have signed on to”
“There was a burning platform”
“to fundamentally simplify and automate and streamline our processes”
Where a supplier can help
- Process automation and ERP
- The third wave of cost work and the single global ERP under RISE's Execute imperative open room for automation, AI and systems integration partners.
- Commercial support for Sports Medicine and Wound growth
- New headcount is going into front-line sales, medical education and customer service in these units: sales enablement, training and CRM tools fit this priority.
- Manufacturing and supply chain
- The Melton plant, site consolidation and inventory rationalisation call for equipment, construction, supply chain analytics and inventory tools.
- Market access and reimbursement
- The skin-substitute reset and payer prior authorisation for SANTYL make reimbursement analytics and market access services relevant to Advanced Wound Management.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Smith+Nephew?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Smith+Nephew Annual Report 2025 (Life Unlimited)
- Smith+Nephew is a UK-listed portfolio medical technology company (founded 1856, ~100 countries served, 16,988 employees) focused on the repair, regeneration and replacement of soft and hard tissue, organised in three global business units: Orthopaedics (40% of Group revenue, $2,437m), Sports Medicine & ENT (31%, $1,934m) and Advanced Wound Management (29%, $1,793m).
- FY2025 revenue was $6,164m, up 6.1% reported and 5.3% underlying (ahead of the ~5% guidance); trading profit rose 15.5% to $1,211m (margin 19.7%, +160bps); operating profit rose 20.7% to $794m; free cash flow rose 52.5% to $840m; adjusted ROIC was 8.3% (+90bps).
- The US is the centre of gravity: US revenue was $3,306m (over 50% of revenue and 35% of employees), and 10 of the 12 Executive Committee members are US-based; China fell to a VBP-driven headwind.
- The three-year 12-Point Plan (2022-2025) is complete: Orthopaedics underlying growth rose from 1.9% in 2022 to 5.1% in 2025, trading margin expanded 240bps since 2022, and free cash flow grew fifteen-fold from $56m in 2022.
- The new RISE strategy (Reach, Innovate, Scale, Execute), launched at the December 2025 Capital Markets Days, targets a 6-7% organic revenue CAGR, 9-10% trading profit CAGR, over $1bn free cash flow and 12-13% adjusted ROIC in 2028, and 300-400bps of Orthopaedics margin expansion by 2028.
- Innovation: $296m R&D in 2025, 15 new products, more than 60% of revenue growth from products launched in the last five years; key platforms are CORI robotics, REGENETEN, CARTIHEAL AGILI-C, PICO, ALLEVYN COMPLETE CARE, the TESSA spatial surgery system and the LANDMARK knee due in H2 2026.
- Capital allocation: $500m share buyback in H2 2025, total dividend 39.1¢ (+4.3%); the $225m (plus up to $225m earn-out) acquisition of Integrity Orthopaedics in January 2026; an inventory portfolio rationalisation programme ($159m provision) meant to release $500m of capital employed.
- 2026 guidance in the report: underlying revenue growth of around 6% and trading profit growth of around 8%, despite headwinds from inventory revaluation, tariffs, US skin-substitute reimbursement changes and ENT VBP in China.
- Smith+Nephew Second Quarter and First Half 2026 Results
- Q2 2026 revenue was $1,597m, +1.6% underlying and +2.8% reported; H1 revenue $3,097m, +2.3% underlying (+3.1% on an average-daily-sales basis) and +4.6% reported.
- H1 trading profit rose 8.1% to $566m (margin 18.3%, +60bps), driven by efficiency savings ($130m realised in H1) and tariff refunds; EPSA +11.0% to 47.7¢; free cash flow $231m; net debt $3,019m, leverage 1.8x.
- Sports Medicine & ENT grew 8.6% underlying in Q2 (Joint Repair +10.6%), while Orthopaedics fell 1.0% (US Knee Implants -7.2%, US Hips -1.5%) and Advanced Wound Management fell 2.1% (Bioactives -12.7% on US skin-substitute reimbursement and a weak SANTYL quarter).
- Full-year underlying revenue growth guidance cut from around 6% to around 4%, but trading profit (around 8% growth ex-acquisitions, around $1.3bn), free cash flow (around $800m) and adjusted ROIC (above 10%) guidance kept, helped by an extra $50m of savings (around $200m for 2026).
- H2 growth expected at 5.0-5.5%, on LEGION MS and the cementless LANDMARK knee, CATALYSTEM hip set deployment, SANTYL recovery, ALLEVYN COMPLETE CARE in Europe, next-generation LEAF and PICO investment.
- RISE milestones: FDA De Novo for TESSA Spatial Surgery, first CORI XT knee and shoulder cases, CATALYSTEM in Japan, Integrity Orthopaedics integration; Melton (UK) wound factory to open in 2027.
- Capital returns: $500m buyback announced in May ($216m settled by 3 August); interim dividend +4.0% to 15.6¢.
- Smith+Nephew Third Quarter 2026 Trading Update (Form 6-K)
- Q3 2026 (quarter to 26 September) revenue was $1,551m, +3.4% on both underlying and reported bases, an acceleration from Q2; nine-month revenue $4,648m, +2.7% underlying.
- Sports Medicine & ENT grew 7.9% underlying ($507m), with Sports Medicine Joint Repair +11.2%; Advanced Wound Management was flat (-0.2%, $454m) as Devices grew 10.7% but Bioactives fell 8.8%; Orthopaedics returned to growth (+2.5%, $590m) though US Knee Implants fell 7.3% and US Hips 1.0%.
- Full-year guidance cut again: underlying revenue growth around 3% (from around 4%), trading profit growth around 4% (from around 8%) to around $1.25bn, free cash flow around $750m (from around $800m), adjusted ROIC around 9% (from more than 10%).
- The Board has "for some months" been considering strategic options for Orthopaedics; it approached Johnson & Johnson about a combination with DePuy Synthes, but those discussions have ended and the review of options continues.
- Investment priority is Sports Medicine and Advanced Wound Management, "where we see a clear route to market leadership".
- Product milestones: 510(k) clearance and first US cases for the cementless LANDMARK knee, first TESSA femoral ACL cases and a filing for tibial use; CORI Hip (Q1 2027) and CORI Hip Impactor (Q3 2027) planned; five-year robotics partnership with Imperial College London.
- More than 50% of Q3 growth came from products launched in the last five years; the $500m buyback is on track with $250m completed by end-Q3.
- Deepak Nath applies pressure at Smith and Nephew (Semafor, The Signal Interview)
- Semafor CEO Signal interview (5 June 2026) with Deepak Nath, CEO since February 2022, six months after he unveiled the RISE three-year plan.
- On the 12-Point Plan: there was "a burning platform"; he chose to "lean into" investor pressure (2024 pay protest vote, Cevian's 5% stake) and chaired a four-hour review meeting every two weeks for four years rather than the planned 18 months.
- China fell from about 7% of the business to around 2% by end-2025 under price controls, which "was nowhere in the plan"; zero-based budgeting brought the plan back on track.
- On targets: "Targets matter, targets are sacrosanct"; RISE was built with a broader cross-section of the company and pressure-tested against scenarios.
- He defends the multi-business portfolio against calls to spin off Orthopaedics, citing past calls to spin off Wound and the shared science across biologics, robotics, software, AI and biomaterials; engagement with Cevian is "very constructive".
- On GLP-1 drugs he sees no fundamental change in joint replacement demand "for the foreseeable future", and possible upsides for knees and sports medicine.
- He calls LANDMARK the company's "most differentiated knee system".
- Smith & Nephew (SNN) Q2 2026 Earnings Call Transcript
- Q2/H1 2026 results call (4 August 2026) with CEO Deepak Nath and CFO John Rogers; Q2 underlying growth of 1.6% was "lower than expected", full-year revenue guidance cut to around 4%, profit, cash and ROIC guidance held.
- Nath says US Orthopaedics weakness is mainly company-specific: the lack of a cementless knee on "one half of our installed base"; the cementless LANDMARK arrives at the very end of Q3 (largely a Q4 effect) and cemented LANDMARK at the end of Q2 2027.
- He still calls Smith+Nephew "fundamentally a 6% to 7% growth company", citing LANDMARK, CORI hip execution, AETOS, the Sports Medicine "big four" (REGENETEN, Integrity/Tendon Seam, CARTIHEAL AGILI-C, TESSA) and PICO, RENASYS and LEAF in Wound.
- Rogers expects Q3 growth similar to Q1's 3.1% and Q4 at 6-7% (just over 5% on a daily-sales basis); 2026 savings raised to around $200m, with a third wave of cost work built on ERP and AI.
- Tariffs: a $60m expected 2026 P&L impact offset by about $50m of refunds, a net cost of about $10m versus $15m in 2025.
- Skin substitutes: revenue down about 20% in H1; headwind at the upper end of $20-40m, with normalisation expected in 2027 at the $127 per square centimetre reimbursement level.
- Headcount grew over 12 months, entirely in Sports and Wound and at least 75% front-line, while manufacturing headcount fell; R&D was protected throughout the 12-Point Plan.
Questions about Smith+Nephew
What does Smith+Nephew do?
It makes medical devices for the repair, regeneration and replacement of soft and hard tissue: orthopaedic implants and robotics, sports medicine and ENT devices, and advanced wound care products.
What is Smith+Nephew's revenue?
Revenue was $6,164m in 2025, up 5.3% underlying. For 2026 the company guides around 3% underlying growth.
How many employees does Smith+Nephew have?
16,988 employees in 2025.
What is Smith+Nephew's strategy?
RISE: reach more patients, innovate, scale Sports Medicine and Wound, and execute efficiently, targeting 6-7% organic revenue growth a year to 2028.
Who leads Smith+Nephew?
Deepak Nath is CEO, John Rogers CFO and Rupert Soames Chair.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)